



Bresso (Milan), 18th January 2016

RE: Clinical study Z7219L02 EVEREST *"A two-year, multicenter, randomized, double-blind, placebo-controlled study to EValuatE the long teRm Efficacy and SafeTy of safinamide 100 mg, once daily, as add-on therapy, in idiopathic Parkinson's Disease patients with motor fluctuations"* EudraCT Number 2014-002600-24.

Dear Ethics Committee/Competent Authority,

We are writing to inform you of the voluntary, business-related decision of the sponsor, Zambon SpA, to close the EVEREST clinical trial of Xadago® (safinamide). In this context, we are kindly asking that the study conduct application is withdrawn.

To date, no patients have been enrolled in this study.

Zambon remains committed to meeting the needs of patients with Parkinson's disease (PD) and to ongoing research in PD and other disorders of the central nervous system.

If you have any questions or require additional information, please contact: Carlo Cattaneo, email: carlo.cattaneo@zambongroup.com.

Asking for your kind relevant actions.

Kindest regards,



Sebastiano Castorina

CEO

Zambon S.p.A.